Trial Profile
Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 10 Feb 2016
Price :
$35
*
At a glance
- Drugs Anifrolumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacodynamics; Pharmacokinetics
- 10 Feb 2016 New trial record